Gennex laboratories Limited has scheduled a board meeting for April 16, 2026, to deliberate on matters related to an upcoming Extraordinary General Meeting (EGM). The pharmaceutical company informed stock exchanges about this development through a regulatory filing dated April 08, 2026.

Meeting Details and Agenda

The board meeting will be conducted on Thursday, April 16, 2026 at 04.00 P.M. at the company's corporate office located at Akash Ganga, Plot 144, Srinagar Colony, Hyderabad, Telangana, 500073. The meeting has been convened in compliance with Regulation 29 of SEBI (LODR) Regulations, 2015.

Key Agenda Items

The board will primarily focus on three significant matters during the meeting:

• Director Regularization: To decide regarding the conduct of Extraordinary General Meeting for regularization of Additional Director Ms. Khushbu Kachhawa (DIN: 10872432) as a Director (Non-Executive Independent Woman Director) of the Company
• Scrutinizer Appointment: To consider and appoint scrutinizer of the Extraordinary General Meeting in case of finalization of the date of EGM
• Additional Business: Any other business with permission of the Chairperson

Regulatory Compliance and Communication

Gennex Laboratories Limited has communicated this development to multiple stock exchanges where its shares are listed. The company has informed BSE Limited (Script Code: 531739), The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited (Script Code: 26178) about the scheduled board meeting.

The intimation has also been uploaded on the company's official website at www.gennexlab.com , ensuring transparency and accessibility for all stakeholders. Company Secretary & Compliance Officer Dinesh Kumar Kejriwal (Membership #A19293) has signed the regulatory filing, which was digitally authenticated on April 08, 2026.

Gennex Laboratories Limited has fulfilled its regulatory obligations by publishing its unaudited financial results for the quarter and nine months ended December 31, 2025, in newspapers as mandated under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance and Publication Details

The company submitted the newspaper publication notice to multiple stock exchanges on February 17, 2026, including BSE Limited (Script Code: 531739), The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited (Scrip Code: 26178). The financial results were published in both Business Standard (English) and Saksham (Telugu - Local) newspapers on Monday, February 16, 2026.

Financial Performance Overview

The unaudited financial results cover both standalone and consolidated figures for the quarter and nine months ended December 31, 2025. These results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on Saturday, February 14, 2026.

Consolidated Results

The consolidated financial results show the company's performance including its subsidiaries. For the quarter ended December 31, 2025, consolidated total income reached ₹10,379.92 thousands compared to ₹4,295.61 thousands in the corresponding quarter of the previous year.

Corporate Governance and Compliance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013. The results have been subjected to limited review by the company's statutory auditors. The company maintains an equity share capital of ₹2,428.48 thousands with a face value of ₹1 per share.

Management and Authorization

The newspaper publication was authorized by Dinesh Kumar Kejriwal, Company Secretary & Compliance Officer (Membership #A19293), and digitally signed on February 17, 2026. The financial results were signed by Arthit Baid, Managing Director (DIN: 01171845), confirming the company's adherence to corporate governance standards.

The complete detailed format of the quarterly financial results is available on the websites of stock exchanges including BSE ( www.bseindia.com ) and on the company's official website ( www.gennexlab.com ) for stakeholder reference.

Source: